ATE324113T1 - Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom - Google Patents

Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom

Info

Publication number
ATE324113T1
ATE324113T1 AT04016883T AT04016883T ATE324113T1 AT E324113 T1 ATE324113 T1 AT E324113T1 AT 04016883 T AT04016883 T AT 04016883T AT 04016883 T AT04016883 T AT 04016883T AT E324113 T1 ATE324113 T1 AT E324113T1
Authority
AT
Austria
Prior art keywords
xanthoma
silyl
dialkyl
treatment
phenol derivatives
Prior art date
Application number
AT04016883T
Other languages
English (en)
Inventor
Simon Jen Tan Mao
Mark Thirston Yates
Roger Alan Parker
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of ATE324113T1 publication Critical patent/ATE324113T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
AT04016883T 1993-12-10 1994-11-03 Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom ATE324113T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16528193A 1993-12-10 1993-12-10

Publications (1)

Publication Number Publication Date
ATE324113T1 true ATE324113T1 (de) 2006-05-15

Family

ID=22598245

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04016883T ATE324113T1 (de) 1993-12-10 1994-11-03 Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom
AT95901141T ATE285238T1 (de) 1993-12-10 1994-11-03 Verfahren zur senkung des serumcholesterinspiegels mit 2,6-dialkyl-4 silyl- phenol derivaten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95901141T ATE285238T1 (de) 1993-12-10 1994-11-03 Verfahren zur senkung des serumcholesterinspiegels mit 2,6-dialkyl-4 silyl- phenol derivaten

Country Status (16)

Country Link
EP (3) EP1468693A3 (de)
JP (1) JPH09511222A (de)
CN (1) CN1092517C (de)
AT (2) ATE324113T1 (de)
AU (1) AU681731B2 (de)
CA (1) CA2177968C (de)
DE (2) DE69434198T2 (de)
DK (2) DK0732928T3 (de)
ES (2) ES2233937T3 (de)
HU (1) HU220761B1 (de)
IL (1) IL111905A (de)
NO (1) NO311868B1 (de)
NZ (1) NZ276285A (de)
PT (2) PT732928E (de)
WO (1) WO1995015760A1 (de)
ZA (1) ZA949663B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2292388C (en) 1997-05-14 2004-07-20 Atherogenics, Inc. Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
CN1147495C (zh) * 1997-06-24 2004-04-28 阿温蒂斯药物公司 用作抗氧剂的烷基-4-甲硅烷基杂环酚类和硫酚类
WO1998058937A1 (en) * 1997-06-25 1998-12-30 Hoechst Marion Roussel, Inc. 2,6-DI-t-BUTYL-4-[ (DIMETHYL-4-METHOXYPHENYLSILYL) -METHYLOXY]PHENOL AND 2,6-DI-t-BUTYL-4-[ (DIMETHYL-2-METHOXY-PHENYLSILYL) -METHYLOXY]PHENOL
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
JP2002511878A (ja) 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
EP1137948B1 (de) * 1998-11-09 2006-05-10 Atherogenics, Inc. Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma
US6887712B1 (en) 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
US6821738B2 (en) 1999-01-20 2004-11-23 The Board Of Regents For Oklahoma State University Broad spectrum bio-detection of nerve agents, organophosphates, and other chemical warfare agents
AU2002248910A1 (en) 2000-11-17 2002-05-27 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrmidines
MXPA04005864A (es) 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
US6960683B2 (en) 2002-07-12 2005-11-01 Atherogenics, Inc. Salt forms of poorly soluble probucol esters and ethers
WO2004108094A2 (en) 2003-06-06 2004-12-16 Atherogenics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
JP2007509054A (ja) * 2003-10-17 2007-04-12 アミリン・ファーマシューティカルズ，インコーポレイテッド 血管健康を促進するシリルフェノール
WO2005112914A2 (en) 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
US8252840B2 (en) 2007-03-26 2012-08-28 Salutria Pharmaceuticals Llc Methods of derivatives of probucol for the treatment of type II diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE349046B (de) * 1966-12-23 1972-09-18 C Guevne
FR2230376A1 (en) * 1973-05-24 1974-12-20 Gueyne Jean Stable solutions of siloxanic polysilanols - prepd. by hydrolysis of a silane and having pharmaceutical activity
FR2308372A2 (fr) * 1975-04-21 1976-11-19 Cortial Produits pharmaceutiques contenant un compose organosilicie en tant qu'agent actif
US4670421A (en) * 1982-07-12 1987-06-02 American Cyanamid Company Antiatherosclerotic silanes
US4900757A (en) * 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
NZ238807A (en) * 1990-07-05 1994-03-25 Merrell Dow Pharma Bis[4-(2,6-dialkyl)phenol]silane derivatives and antiatherosclerotic compositions
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents

Also Published As

Publication number Publication date
DK1468692T3 (da) 2006-08-28
DE69434198D1 (de) 2005-01-27
EP1468693A3 (de) 2004-11-03
CN1140995A (zh) 1997-01-22
IL111905A0 (en) 1995-03-15
EP0732928B1 (de) 2004-12-22
JPH09511222A (ja) 1997-11-11
DK0732928T3 (da) 2005-04-18
DE69434720T2 (de) 2007-05-16
NO311868B1 (no) 2002-02-11
DE69434198T2 (de) 2005-12-29
ATE285238T1 (de) 2005-01-15
NO962415D0 (no) 1996-06-07
HU220761B1 (hu) 2002-05-28
HUT74015A (en) 1996-10-28
CA2177968A1 (en) 1995-06-15
AU681731B2 (en) 1997-09-04
NZ276285A (en) 2004-11-26
ES2233937T3 (es) 2005-06-16
HU9601590D0 (en) 1996-08-28
IL111905A (en) 2001-04-30
ZA949663B (en) 1995-08-15
DE69434720D1 (de) 2006-06-01
CA2177968C (en) 2000-03-28
EP1468693A2 (de) 2004-10-20
PT1468692E (pt) 2006-09-29
NO962415L (no) 1996-06-07
AU1049995A (en) 1995-06-27
ES2263094T3 (es) 2006-12-01
CN1092517C (zh) 2002-10-16
WO1995015760A1 (en) 1995-06-15
EP1468692B1 (de) 2006-04-26
PT732928E (pt) 2005-03-31
EP1468692A2 (de) 2004-10-20
EP1468692A3 (de) 2004-11-03
EP0732928A1 (de) 1996-09-25

Similar Documents

Publication Publication Date Title
DE69434720D1 (de) Verwendung von 2,6-Dialkyl-4-Silyl-Phenol Derivaten zur Behandlung von Xanthom
NO179142C (no) 3-benzyliden-1-karbamoyl-2-pyrrolidon-analoger
DE69736642D1 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
NO308739B1 (no) Imidazolderivater samt medisinsk sammensetning og anti-HIV- sammensetning omfattende samme
LU91196I2 (fr) Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO).
ATE202702T1 (de) Verwendung von oestrogenagonisten und - antagonisten zur herstellung eines medikaments zur behandlung von atherosklerose, unabhängig von lipidsenkung
EP0632031A4 (de)
DK0490566T3 (da) Fremstilling og anvendelse af N-iodpropargyloxycarbonylaminosyreestere og derivater som antimikrobielle midler
ATE181066T1 (de) Zwischenverbindungen zur herstellung von thioalkylthio cephalosporinderivaten
NZ218243A (en) B-carboline derivatives and pharmaceutical compositions
EP0712398A1 (de) Benzopyrane und diese enthaltende pharmazeutische zusammenstellungen
SE8303913D0 (sv) Heterocykliska foreningar
DE69016866D1 (de) Verwendung von Bis(4-hydroxyphenylthio)methan-Derivaten zur Behandlung von Diabetes mellitus.
ATE215075T1 (de) Hydroxylamin-derivate mit anti-ischämischer wirkung und pharmazeutische zusammensetzungen diese enthaltend
DE69027328D1 (de) Indeno-d-pyrimidonverbindungen zur Verwendung in der Medizin
DK0579169T3 (da) Alkylendiaminderivater
ATE143591T1 (de) Verwendung von bis-(p- hydroxyphenylthio)methanderivaten zur hemmung der fortschreitenden entwicklung von insulinabhängingem diabetes mellitus
EA200200462A1 (ru) Производные 2-арилхинолина, их получение и терапевтическое применение
FI935399L (fi) N-substituerade azabicykloheptanderivat samt deras framstaellning och anvaendning

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1468692

Country of ref document: EP

REN Ceased due to non-payment of the annual fee